Peptide Drugs: Current Status and It's Applications in the Treatment of Various Diseases

Overview

Journal Curr Drug Res Rev

Publisher Bentham Science Publishers

Specialties Pharmacology
Psychiatry

Date 2024 Apr 19

PMID 38638039

Authors

Chandni Chandarana

Isha Juwarwala

Shravi Shetty

Anushree Bose

Affiliations

Soon will be listed here.

Abstract

Peptides represent a class of natural molecules with diverse physiological functions, including hormone regulation, neurotransmission, and immune modulation. In recent years, peptide- based therapeutics have gained significant attention in pharmaceutical research and development due to their high specificity, efficacy, and relatively low toxicity. This review provides an overview of the current landscape of peptide drug development, highlighting the challenges faced in their formulation and delivery and the innovative strategies employed to overcome these hurdles. The review explores the wide range of applications of peptide drugs in treating various diseases, including HIV, multiple sclerosis, osteoporosis, chronic pain, diabetes, and cancer. Examples of FDA-approved peptide drugs and ongoing clinical trials are presented, showcasing the continuous advancements in peptide-based therapeutics across different therapeutic areas. This review underscores the promising potential of peptide drugs as targeted and effective treatments for a multitude of medical conditions, offering improved therapeutic outcomes and enhanced patient care.

Citing Articles

Stapled Peptides: An Innovative and Ultimate Future Drug Offering a Highly Powerful and Potent Therapeutic Alternative.

Kim D, Kang S Biomimetics (Basel). 2024; 9(9).

PMID: 39329559 PMC: 11430733. DOI: 10.3390/biomimetics9090537.

References

Lau J, Dunn M . Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2017; 26(10):2700-2707. DOI: 10.1016/j.bmc.2017.06.052. View

Fosgerau K, Hoffmann T . Peptide therapeutics: current status and future directions. Drug Discov Today. 2014; 20(1):122-8. DOI: 10.1016/j.drudis.2014.10.003. View

Chupradit K, Moonmuang S, Nangola S, Kitidee K, Yasamut U, Mougel M . Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era. Viruses. 2017; 9(10). PMC: 5691633. DOI: 10.3390/v9100281. View

Sharp P, Hahn B . Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2012; 1(1):a006841. PMC: 3234451. DOI: 10.1101/cshperspect.a006841. View

Cena-Diez R, Narayanan A, Ray S, van de Klundert M, Rodriguez J, Nilvebrant J . Naturally occurring dipeptide from elite controllers with dual anti-HIV-1 mechanism. Int J Antimicrob Agents. 2023; 61(5):106792. DOI: 10.1016/j.ijantimicag.2023.106792. View

Shi S, Nguyen P, Cabral H, Diez-Barroso R, Derry P, Kanahara S . Development of peptide inhibitors of HIV transmission. Bioact Mater. 2018; 1(2):109-121. PMC: 5883972. DOI: 10.1016/j.bioactmat.2016.09.004. View

Craik D, Fairlie D, Liras S, Price D . The future of peptide-based drugs. Chem Biol Drug Des. 2012; 81(1):136-47. DOI: 10.1111/cbdd.12055. View

Choonara B, Choonara Y, Kumar P, Bijukumar D, du Toit L, Pillay V . A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv. 2014; 32(7):1269-1282. DOI: 10.1016/j.biotechadv.2014.07.006. View

Kitchen C, Nuno M, Kitchen S, Krogstad P . Enfuvirtide antiretroviral therapy in HIV-1 infection. Ther Clin Risk Manag. 2008; 4(2):433-9. PMC: 2504070. DOI: 10.2147/tcrm.s1962. View

10.

Wild C, Shugars D, Greenwell T, McDanal C, Matthews T . Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994; 91(21):9770-4. PMC: 44898. DOI: 10.1073/pnas.91.21.9770. View

11.

Chen C, Matthews T, McDanal C, Bolognesi D, Greenberg M . A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol. 1995; 69(6):3771-7. PMC: 189094. DOI: 10.1128/JVI.69.6.3771-3777.1995. View

12.

Pert C, Hill J, Ruff M, Berman R, Robey W, Arthur L . Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci U S A. 1986; 83(23):9254-8. PMC: 387114. DOI: 10.1073/pnas.83.23.9254. View

13.

Alam S, Paleos C, Liao H, Scearce R, Robinson J, Haynes B . An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. AIDS Res Hum Retroviruses. 2004; 20(8):836-45. DOI: 10.1089/0889222041725181. View

14.

Weinstock-Guttman B, Jacobs L . What is new in the treatment of multiple sclerosis?. Drugs. 2000; 59(3):401-10. DOI: 10.2165/00003495-200059030-00002. View

15.

. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998; 352(9139):1498-504. View

16.

Del Gatto A, Saviano M, Zaccaro L . An Overview of Peptide-Based Molecules as Potential Drug Candidates for Multiple Sclerosis. Molecules. 2021; 26(17). PMC: 8434400. DOI: 10.3390/molecules26175227. View

17.

Baldassari L, Feng J, Clayton B, Oh S, Sakaie K, Tesar P . Developing therapeutic strategies to promote myelin repair in multiple sclerosis. Expert Rev Neurother. 2019; 19(10):997-1013. DOI: 10.1080/14737175.2019.1632192. View

18.

Rayatpour A, Javan M . Targeting the brain lesions using peptides: A review focused on the possibility of targeted drug delivery to multiple sclerosis lesions. Pharmacol Res. 2021; 167:105441. DOI: 10.1016/j.phrs.2021.105441. View

19.

Yuan R, Wang B, Lu W, Maeda Y, Dowling P . A Distinct Region in Erythropoietin that Induces Immuno/Inflammatory Modulation and Tissue Protection. Neurotherapeutics. 2015; 12(4):850-61. PMC: 4604189. DOI: 10.1007/s13311-015-0379-1. View

20.

Miller S, Turley D, Podojil J . Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol. 2007; 7(9):665-77. DOI: 10.1038/nri2153. View